Upgrade to Finviz Elite: Get our fastest platform speed, real-time data, and unlimited screening & charting. Start Free Trial

RGNT

Regentis Biomaterials Ltd

Feb 06 • 04:00PM ET

4.83

+0.02 0.42 %

Healthcare • Medical Instruments & Supplies • Israel • AMEX

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-1.15	Insider Own	40.36%	Shs Outstand	4.93M	Perf Week	-16.72%
Market Cap	25.02M	Forward P/E	-	EPS next Y	-	Insider Trans	0.00%	Shs Float	3.09M	Perf Month	-28.76%
Enterprise Value	68.09M	PEG	-	EPS next Q	-	Inst Own	5.72%	Short Float	0.04%	Perf Quarter	-
Income	-5.66M	P/S	-	EPS this Y	-	Inst Trans	0.00%	Short Ratio	0.03	Perf Half Y	-
Sales	0.00M	P/B	-	EPS next Y	-	ROA	-1676.79%	Short Interest	0.00M	Perf YTD	-28.34%
Book/sh	-8.99	P/C	131.68	EPS next 5Y	-	ROE	-	52W High	8.35 -42.16%	Perf Year	-
Cash/sh	0.04	P/FCF	-	EPS past 3/5Y	- -	ROIC	-	52W Low	4.37 10.53%	Perf 3Y	-
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	-	Volatility	7.25% 11.05%	Perf 5Y	-
Dividend TTM	-	EV/Sales	-	EPS Y/Y TTM	72.10%	Oper. Margin	-	ATR (14)	0.61	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	0.05	Sales Y/Y TTM	-	Profit Margin	-	RSI (14)	25.84	Recom	-
Dividend Gr. 3/5Y	- -	Current Ratio	0.05	EPS Q/Q	-	SMA20	-24.42%	Beta	-	Target Price	-
Payout	-	Debt/Eq	-	Sales Q/Q	-	SMA50	-27.21%	Rel Volume	0.56	Prev Close	4.81
Employees	10	LT Debt/Eq	-	Earnings	-	SMA200	-27.21%	Avg Volume	36.13K	Price	4.83
IPO	Dec 04, 2025	Option/Short	No / Yes	EPS/Sales Surpr.	- -	Trades		Volume	20,110	Change	0.42%

Feb-04-26 08:33AM	Regentis Biomaterials Appoints Ori Gon as Chief Financial Officer and Chief Business Officer as GelrinC Progresses Towards Commercial Launch in Europe and Advances in U.S. Phase III FDA Trial (ACCESSWIRE)
Jan-29-26 08:33AM	Regentis Expanding Pivotal Phase III GelrinC Clinical Site Network: Adding Several Leading Orthopedic Centers Across the U.S. (ACCESSWIRE)
Jan-20-26 08:33AM	Regentis' GelrinC Demonstrates Breakthrough in Regenerating Native-Like Cartilage Structure in Knee Repair on MRI Results Confirmed Using a Validated, Regulator-Accepted Method (ACCESSWIRE)
Jan-06-26 08:21AM	Regentis' GelrinC Establishes Long-Term Durability of Cartilage Repair Through Quantitative MOCART Evaluation (ACCESSWIRE)
Dec-18-25 08:35AM	Regentis Biomaterials Granted New U.S. Patent for its Off-the-Shelf Regenerative Cartilage Repair Product GelrinC (ACCESSWIRE)
04:10PM	Loading…
Dec-05-25 04:10PM	Regentis Biomaterials Ltd. Announces Closing of Initial Public Offering (GlobeNewswire)
Dec-03-25 07:23PM	Regentis Biomaterials Ltd. Announces Pricing of Initial Public Offering (GlobeNewswire)

Regentis Biomaterials Ltd. engages in the development of tissue repair solutions. It focuses on orthopedic treatments through its Gelrin platform based on degradable hydrogel implants to regenerate damaged or diseased tissue such as inflamed cartilage and bone tissue. The company was founded by Dror Seliktar and Tal Yehiel on September 1, 2004 and is headquartered in Or-Akiva, Israel.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

RGNT

Regentis Biomaterials Ltd

Upgrade your FINVIZ experience